Solas Medical

Why Solas costs 50–70% less than the competition

A straightforward explanation of where the savings come from, and why they don't come at the expense of clinical quality.

The bill of materials problem

When you buy an aesthetic laser from Cynosure, Cutera, Lumenis, or Sciton, you're not just paying for the device. You're paying for everything it took to build and sell it at scale. That overhead is baked into the price, and it is substantial.

Here's a conservative breakdown of what incumbent pricing funds:

None of those line items appear on the device itself. None of them affect whether the laser delivers a precise 532 nm pulse or ablates tissue to the correct depth. They're purely the cost of running a large commercial enterprise around a medical device, and they get passed directly to the buyer.

For a $200,000 incumbent system, a realistic estimate is that $80,000 to $120,000 of that price reflects sales infrastructure and overhead, not hardware. Solas eliminates most of that cost at the source.

What Solas does differently

Solas Medical was founded by Ciaran Smythe, a physician-engineer who designs the devices himself. That single fact changes the entire cost structure.

Ciaran sources components directly from the same medical-grade suppliers that supply the major manufacturers. Not comparable suppliers. Not offshore alternatives. The same tier of components: the identical optical, electronic, and mechanical parts used in devices that sell for two to three times the price. Solas claims same-grade, not superior. The difference isn't in the raw materials. It's in what happens between the factory and the clinic.

Assembly happens in-house, by a team Ciaran oversees directly. There's no contract manufacturer adding a margin. There's no distributor taking a cut between production and delivery. There's no commissioned sales floor marking up the final price to cover quota-driven compensation.

Celeste Murray handles outbound sales. She is the entire outbound team. That's the model. You get a direct conversation with someone who knows the product deeply, no intermediaries, no territorial conflicts. The savings from not running a national sales organization flow entirely to the buyer.

What that means for clinical credibility

FDA clearance does not scale with marketing budget. A 510(k) clearance granted to Solas Medical carries the same regulatory weight as one granted to Cynosure. The cleared indications, the safety requirements, the labeling obligations are identical. Brand size is not a variable in that process.

The treatment protocols are physician-developed and histology-confirmed. Parameters have been validated against tissue response, not optimized for demo videos. When a protocol ships with a device, it comes from clinical work, not marketing collateral.

Ciaran is reachable for technical questions. Not a support ticket queue, not a regional rep who escalates to a clinical team. The physician who designed the device. For practices evaluating clinical edge cases or protocol customization, that access is meaningfully different from what incumbent brands offer.

Why the savings can't be matched by going used

The natural reflex when a new device seems underpriced is to compare it to the used market. It's worth being precise about why a new Solas device is a different category than a used incumbent at a similar price point.

A new Solas device ships with a full manufacturer warranty. A used device ships with whatever the prior owner's maintenance history was, which may be unknown, incomplete, or undisclosed. Laser systems degrade. Optical components drift. Handpiece integrity wears with use. Buying used means buying a machine whose remaining useful life is already partially spent.

Current-generation hardware matters for clinical capability. A used system may represent technology from three to seven product cycles ago, before improvements in pulse shaping, spot size consistency, or cooling system reliability that affect treatment outcomes.

Training is included with every Solas purchase. Used device sales are typically asset-only transactions. The buyer acquires the hardware and figures out the rest. Solas provides physician-developed protocols and hands-on training as part of the purchase. That's a tangible difference in what the practice is actually acquiring.

What the customer pays for

The price of a Solas device covers two things: the device, and the physician-developed training to use it effectively.

That's the complete list. There is no national sales infrastructure embedded in the price. No distributor margin. No trade show overhead. No executive compensation stack. The cost of running a large commercial organization around the product isn't there because the large commercial organization isn't there. What you pay for is what you receive.

What this isn't

The price point creates predictable assumptions. Most of them are wrong, and it's worth being direct about that.

Solas is not a budget brand. Budget implies a compromise in materials, manufacturing standards, or clinical validation. Solas makes no such compromise. The component grade is the same. The FDA clearance process is the same. The clinical validation is the same.

Solas is not a value sub-brand created by an incumbent to compete at a lower price tier. There's no parent company with a premium line. This is the line.

Solas is not a Chinese OEM rebrand. The devices are designed by Ciaran Smythe and assembled domestically under his direct oversight. The provenance of the hardware is not a question mark.

Solas is not selling refurbished or gray-market equipment. Every device is new. Every device ships with a full warranty. The transaction is straightforward.

The price is not a promotion. There's no introductory period, no limited-time offer, no catch revealed after the sale. This is the operating cost of a physician-founded, direct-to-practice medical device company, and it is structurally lower than the alternative.

See the product line → Talk to Celeste →